The global dupuytrens disease market has been witnessing significant growth in recent years. Dupuytrens disease is a condition characterized by the formation of connective tissue growth under the skin of the palm, causing a firm thickening or cord. The disease causes fingers to slowly curl towards the palm. The current standard treatment options for this condition include needle fasciotomy, collagenase clostridium histolyticum (CCH) injection, and surgery. CCH injection is the non-surgical option that breaks down the collagen bands causing the curvature. However, needle fasciotomy and surgery are still widely used especially in advanced-stage conditions.

The global Dupuytrens Disease Market is estimated to be valued at Us$ 4.3 Bn in 2024 and is expected to exhibit a CAGR Of 4.6% over the forecast period 2024 To 2030.

The growth can be attributed to the rising geriatric population globally who are more prone to develop this condition. According to WHO, the geriatric population is expected to reach 2 billion by 2050 from 900 million in 2015. The increasing cases of diabetes mellitus, which is a risk factor for Dupuytren’s disease, is also fueling the market growth.

Key Takeaways

Key players operating in the Global Dupuytrens Disease Market Demand  are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp. Emergence of newer injectable treatment options like CCH is a major opportunity for players in this market.

Advantages offered by minimally invasive treatment procedures like CCH injection over surgeries has increased their adoption rate globally. This has prompted companies to invest more in developing safer and effective non-surgical treatment options. North America dominates the market currently due to high awareness and advanced healthcare infrastructure. However, Asia Pacific region is expected to offer lucrative growth opportunities during the forecast period with China and India being the major markets.

Market drivers

The key driver influencing the growth of global dupuytrens disease market is the rising geriatric population globally. As per the United Nations data, the proportion of global population aged over 60 years is projected to double from 12% to 22% between 2015 and 2050. Older population is more susceptible to develop dupuytrens disease. Increasing prevalence of diabetes and other autoimmune diseases also act as a growth driver for this market. These conditions are linked with higher risks of developing dupuytrens disease.

PEST Analysis

Political: Changes in healthcare regulations may impact the availability and pricing of treatment options for Dupuytrens disease. Government initiatives to improve patient access to new treatment options can positively influence the market.

Economic: A stable economic environment favoring healthcare investments from pharma companies promotes research and development of advanced treatment options fueling market growth.

Social: Growing awareness about available treatment and management options helps more patients seek medical care reducing stigma associated with the condition boosting demand.

Technological: Advancements in non-surgical and minimally invasive treatment procedures like collagenase injections and new drug therapies provide alternatives to surgical treatments improving patient outcomes and market prospects over the forecast period. Developments in hand reconstruction techniques expand treatment opportunities.

Geographical Regions of Concentrated Market Value

The regions of North America and Europe account for a major share of the global Dupuytren’s disease market value currently due to high disease prevalence, regulatory approvals of newer treatment options, advanced healthcare infrastructure and presence of key market players in these regions.

Fastest Growing Regional Market

The Asia Pacific region is projected to witness the fastest growth in the Dupuytren’s disease market during the forecast period supported by growing medical tourism, rising healthcare spending, increasing patient access to diagnosis and treatment due to expanding insurance coverage in key country markets like China and India.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it